Vaxart (OTCMKTS:VXRT) Stock Price Passes Above Fifty Day Moving Average – What’s Next?

Shares of Vaxart, Inc. (OTCMKTS:VXRT) passed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $0.53 and traded as high as $0.6399. Vaxart shares last traded at $0.6380, with a volume of 212,247 shares traded.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded shares of Vaxart to a “buy” rating in a research report on Friday, January 23rd. One research analyst has rated the stock with a Buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $2.00.

Vaxart Stock Performance

The business’s 50-day moving average is $0.53 and its two-hundred day moving average is $0.42. The firm has a market capitalization of $153.43 million, a price-to-earnings ratio of -2.77 and a beta of 1.19.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Creative Planning acquired a new stake in shares of Vaxart during the second quarter worth about $33,000. Goldman Sachs Group Inc. bought a new stake in Vaxart during the 1st quarter worth approximately $31,000. Invesco Ltd. raised its holdings in Vaxart by 93.1% during the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock worth $60,000 after buying an additional 70,568 shares during the period. Raymond James Financial Inc. lifted its stake in Vaxart by 16.9% in the second quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company’s stock valued at $107,000 after buying an additional 34,075 shares in the last quarter. Finally, Jones Financial Companies Lllp boosted its holdings in shares of Vaxart by 276,364.7% in the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock valued at $196,000 after buying an additional 478,111 shares during the period. 18.05% of the stock is currently owned by institutional investors.

Vaxart Company Profile

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.